Menu
iPMI Magazine Is Proudly Sponsored By:
For a healthier journey.

iPMI Magazine Has Moved

iPMI Magazine successfully rebranded to iPMI Global in 2023 and has moved to a new home on the internet. To visit the brand new international private medical insurance business intelligence platform, please go to www.ipmiglobal.com

Interpace Diagnostics Announces Additional Coverage in Top Managed Care Health Plans for Their Thyroid and Pancreas Molecular Diagnostic Tests

Interpace Diagnostics Announces Additional Coverage in Top Managed Care Health Plans for Their Thyroid and Pancreas Molecular Diagnostic Tests

PDI, Inc. subsidiary Interpace Diagnostics announced today that both the ThyGenX™ Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier, its molecular diagnostic tests for indeterminate thyroid nodules, are now covered by one of the largest independent Blue Cross Blue Shield plans that insures 3.3 million lives. 

This medical policy update, covering both ThyGenX and ThyraMIR, represents the first large commercial plan to cover ThyraMIR, a novel microRNA gene expression classifier launched earlier this year. Furthermore, it follows the recent announcement of coverage by Aetna for ThyGenX, Interpace Diagnostics' genetic mutation panel used to improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis of thyroid cancer.  The combination of all plans, including Medicare coverage of ThyGenX, represents a total of 80 million covered lives for Interpace Diagnostics' molecular thyroid diagnostic tests.

Coverage of PancraGen™, Interpace Diagnostics' test for pancreatic cyst cancer risk stratification, was also recently extended to an additional 1.3 million lives by a contracted top national plan, bringing this plan's total covered lives for PancraGen to 10 million.  Additionally, one of the country's largest Blue Cross Blue Shield plans renewed PancraGen contract coverage for their 5.9 million lives. These plans recognize the value in identifying patients at risk of progression to pancreatic cancer and those at a lower risk with a high degree of accuracy, by ensuring their members have access to this technology.  The combination of all plans, including Medicare coverage of PancraGen, represents over 70 million covered lives for this molecular test.

"Coverage by these additional plans provides further validation of our tests' value to their members," said Nancy Lurker, CEO of PDI, Inc.  She adds, "We continue to advance discussions with other plans to increase coverage for our tests, efforts which will both benefit patients and further accelerate the current growth taking place at Interpace Diagnostics, our molecular diagnostics business."

back to top